12 completed, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 9 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow bioRASI, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris B244, Vehicle - Acne Vulgaris | Phase 2 | Not yet recruiting | AOBiome LLC | 176 | 2026-10-01 | 2026-10-08 |
| Study in Subjects With Mild-to-Moderate Alzheimer's Dementia ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Alzamend Neuro, Inc. | 30 | 2023-07-05 | 2026-09-30 |
| Lomecel-B Effects on Alzheimer's Disease Allogeneic MSC, Placebo - Mild Alzheimer's Disease | Phase 2 | Completed | Longeveron Inc. | 50 | 2021-12-28 | 2024-02-20 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Rifaximin, Placebo - Papulopustular Rosacea | Phase 2 | Completed | Alfasigma S.p.A. | 216 | 2021-10-05 | 2024-04-24 |
| A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 hMSC - Covid19 | Phase 2 | Unknown | Stemedica Cell Technologies, Inc. | 40 | 2021-03-20 | 2022-07-08 |
| B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis B244, Vehicle - Atopic Dermatitis, Pruritus | Phase 2 | Completed | AOBiome LLC | 547 | 2020-06-24 | 2025-01-28 |
| A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) GB0139, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Completed | Galecto Biotech AB | 172 | 2019-02-19 | 2024-05-22 |
| A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea B244, Vehicle - Rosacea | Phase 2 | Completed | AOBiome LLC | 140 | 2018-07-02 | 2022-09-16 |
| Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel - External Anogenital Warts | Phase 3 | Completed | Dermax SA | 466 | 2018-04-20 | 2021-07-27 |
| A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies Permethrin Cream 5% - Scabies | Phase 3 | Completed | Saptalis Pharmaceuticals LLC | 126 | 2018-04-10 | 2020-10-23 |
| A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice Ivermectin 0.5% Topical Application Lotion, Ivermectin 0.5% Topical Application Lotion [SKLICE], Placebo 0% Lotion - Head Lice | Phase 3 | Completed | Mayne Pharma International Pty Ltd | 296 | 2017-10-02 | 2020-09-17 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Permethrin Cream, 5%, Elimite - Scabies | Phase 3 | Completed | Mayne Pharma International Pty Ltd | 140 | 2016-11-01 | 2020-09-02 |
| A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel - Papulopustular Rosacea, Erythematotelangiectatic Rosacea | Phase 3 | Completed | bioRASI, LLC | 963 | 2015-02-01 | 2020-09-03 |
| Bio-equivalence Study Between SAPHRIS and Asenapine SAPHRIS, Asenapine - Schizophrenia, Bipolar Disorder | Phase 1 | Completed | Sun Pharmaceutical Industries Limited | 65 | 2013-07-01 | 2021-04-30 |
Rosacea (3) · Scabies (2) · Acne Vulgaris (1) · Alzheimer Disease (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Bipolar Disorder (1) · COVID-19 (1) · Dermatitis, Atopic (1) · Gallbladder Neoplasms (1) · Idiopathic Pulmonary Fibrosis (1) · Neoplasms (1) · Pruritus (1) · Schizophrenia (1)
ARRY-334543 (1) · Capecitabine (1) · GB-0139 (1) · Ivermectin (1) · Metronidazole (1) · Permethrin (1) · Rifaximin (1) · asenapine (1)
United States (14) · Australia (2) · Poland (2) · Russia (2) · Spain (2) · Ukraine (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Georgia (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Ireland (1)
Hyun Kim, PhD (2) · David Walling, MD (1) · Evagelos Coskinas, MD (1) · Evgeniy Cherepanov, MD (1) · Gilbert R. Weiner, DO (1) · James S. McDonough, MD (1) · Jim G. Aukstuolis, MD (1) · Judith Ng-Cashin, MD (1) · Kurian Abraham, MD (1) · Lev Verkh, PhD/MS (1) · Phoevos Hughes, JD (1) · Robert A Riesenberg, MD (1) · Santosh Kesari, MD (1) · Spiros Jamas, ScD (1) · Toby Maher, MD, PhD (1)
PMID 33072090, PMID 35120836, PMID 37396805, PMID 40065171
2018 (1)